Contract development and manufacturing organisation (CDMO), Avara Pharmaceutical Services, has acquired the Italian sterile manufacturing facility in an agreement with Pfizer.
Italian flag
“This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand,” stated Timothy C. Tyson, chairman and CEO of Avara Pharmaceutical Services.
The CDMO provides both active pharmaceutical ingredient (API) formulation and manufacturing, as well as secondary formulation, manufacturing and packaging of small molecule drugs, including highly potent compounds. Additionally, the company has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules.
With this new acquisition, Avara Pharmaceutical Services has six sites. Two are based in the US, one in Puerto Rico, one in the UK, one in Ireland and now one in Liscate, Italy.
“As we celebrate another important milestone, we continue with great confidence to build a pharmaceutical services company with complementary offerings in key regions in this rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people who are a part of the Avara team are the key to our long-term success,” said Tyson. “We are focused on delivering on our commitments and earning the trust of every customer we deal with.”